SCCA's Dr. Mazyar Shadman presents his first abstract, Safety and Efficacy of Third Generation CD20 Targeted CART (MB106) for Treatment of Relapsed/Refractory BNHL and CLL at the 63rd ASH Annual Meeting and Exposition. Learn more about SCCA's appearance at ASH 2021 at https://www.seattlecca.org/conference...